Class Action Lawsuit Filed Against Alto Neuroscience Over Misleading Public Statements

Strategic Insights -

Alto Neuroscience, a clinical-stage biopharmaceutical company, has been sued in a class action lawsuit over allegedly misleading public statements regarding its product, ALTO-100, which was being tested as a treatment for patients with major depressive disorder. The lawsuit claims that the company's registration statement, prospectus, and other public statements were negligently prepared and contained untrue statements of material fact. The lawsuit was filed by Pomerantz LLP on behalf of investors who purchased or acquired Alto securities between February 2, 2024, and October 22, 2024. The lawsuit alleges that the company's statements about ALTO-100's clinical, regulatory, and commercial prospects were overstated, and that the company's stock price fell significantly after the announcement of the Phase 2b trial's topline results.

Key Takeaways:

  • The class action lawsuit was filed against Alto Neuroscience by Pomerantz LLP on behalf of investors who purchased or acquired Alto securities between February 2, 2024, and October 22, 2024.
  • The lawsuit claims that Alto's registration statement, prospectus, and other public statements were negligently prepared and contained untrue statements of material fact.
  • Allegedly, Alto's statements about ALTO-100's clinical, regulatory, and commercial prospects were overstated, and that the company's stock price fell significantly after the announcement of the Phase 2b trial's topline results.
  • The lawsuit specifically alleges that ALTO-100 was less effective in treating MDD than Defendants had led investors to believe.
  • Alto's common stock began publicly trading on the New York Stock Exchange under the ticker symbol "ANRO" on February 2, 2024.
  • The company issued 8,040,000 shares of its common stock to the public at the Offering price of $16.00 per share.

Statistics:

  • The class action lawsuit seeks to represent all investors who purchased or acquired Alto securities between February 2, 2024, and October 22, 2024.
  • Alto's common stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024, after the announcement of the Phase 2b trial's topline results.
  • Alto issued 8,040,000 shares of its common stock to the public at the Offering price of $16.00 per share.
  • The company raised $119,635,200 in proceeds from the initial public offering (IPO).

Sources:

  • "Class action lawsuit filed against Alto Neuroscience, Inc." Pomerantz LLP
  • Form S-1 registration statement, filed by Alto Neuroscience, Inc. with the United States Securities and Exchange Commission (SEC)
  • Form 424B4 prospectus, filed by Alto Neuroscience, Inc. with the SEC
  • "Alto Neuroscience, Inc. (ANRO) News," Bloomberg.com
  • "Class Action Lawsuit Filed Against Alto Neuroscience, Inc.," Law360.com